

# Murray D Krahn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/400291/publications.pdf>

Version: 2024-02-01

349  
papers

15,716  
citations

19657

61  
h-index

23533

111  
g-index

355  
all docs

355  
docs citations

355  
times ranked

19472  
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses. JAMA - Journal of the American Medical Association, 2016, 316, 1093.	7.4	2,149
2	Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology, 2008, 48, 418-431.	7.3	714
3	Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. Aids, 2008, 22, 1979-1991.	2.2	348
4	Association of Temporal Trends in Risk Factors and Treatment Uptake With Coronary Heart Disease Mortality, 1994-2005. JAMA - Journal of the American Medical Association, 2010, 303, 1841.	7.4	253
5	The effect of English language proficiency on length of stay and in-hospital mortality. Journal of General Internal Medicine, 2004, 19, 221-228.	2.6	251
6	Health-State Utilities and Quality of Life in Hepatitis C Patients. American Journal of Gastroenterology, 2003, 98, 630-638.	0.4	243
7	Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses. Gastroenterology, 2010, 139, 1218-1229.e5.	1.3	227
8	Primer on Medical Decision Analysis: Part 2â€”Building a Tree. Medical Decision Making, 1997, 17, 126-135.	2.4	225
9	The Next Step in Guideline Development. JAMA - Journal of the American Medical Association, 2008, 300, 436.	7.4	223
10	Conceptualizing a Model. Medical Decision Making, 2012, 32, 678-689.	2.4	216
11	Primer on Medical Decision Analysis: Part 1â€”Getting Started. Medical Decision Making, 1997, 17, 123-125.	2.4	215
12	Primer on Medical Decision Analysis: Part 5â€”Working with Markov Processes. Medical Decision Making, 1997, 17, 152-159.	2.4	209
13	Primer on Medical Decision Analysis: Part 3â€”Estimating Probabilities and Utilities. Medical Decision Making, 1997, 17, 136-141.	2.4	207
14	Screening for Prostate Cancer. JAMA - Journal of the American Medical Association, 1994, 272, 773.	7.4	186
15	Management of neck pain and associated disorders: A clinical practice guideline from the Ontario Protocol for Traffic Injury Management (OPTIMA) Collaboration. European Spine Journal, 2016, 25, 2000-2022.	2.2	173
16	30-Day Mortality and Major Complications after Radical Prostatectomy: Influence of Age and Comorbidity. Journal of the National Cancer Institute, 2005, 97, 1525-1532.	6.3	172
17	Discounting in the Economic Evaluation of Health Care Interventions. Medical Care, 1993, 31, 403-418.	2.4	165
18	Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Value in Health, 2012, 15, 804-811.	0.3	160

#	ARTICLE	IF	CITATIONS
19	Primer on Medical Decision Analysis: Part 4-Analyzing the Model and Interpreting the Results. Medical Decision Making, 1997, 17, 142-151.	2.4	157
20	Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer?. Journal of Clinical Oncology, 2003, 21, 3318-3327.	1.6	157
21	Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 5038-5045.	1.6	157
22	Acute Appendicitis in Young Children: Cost-effectiveness of US versus CT in Diagnosis—A Markov Decision Analytic Model. Radiology, 2009, 250, 378-386.	7.3	149
23	Prostate Cancers Scored as Gleason 6 on Prostate Biopsy are Frequently Gleason 7 Tumors at Radical Prostatectomy: Implication on Outcome. Journal of Urology, 2006, 176, 979-984.	0.4	132
24	Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. Osteoporosis International, 2013, 24, 659-669.	3.1	124
25	Kidney Transplantation in the Elderly. Journal of the American Society of Nephrology: JASN, 2003, 14, 187-196.	6.1	120
26	Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature. Pharmacoeconomics, 2017, 35, 727-740.	3.3	116
27	Comparative Effectiveness of the Core Components of Cardiac Rehabilitation on Mortality and Morbidity: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 2018, 7, 514.	2.4	114
28	Patient and Community Preferences for Outcomes in Prostate Cancer. Medical Care, 2003, 41, 153-164.	2.4	113
29	The Economic Impact of Clostridium difficile Infection: A Systematic Review. American Journal of Gastroenterology, 2015, 110, 511-519.	0.4	107
30	Utility-based Quality of Life Measures in Alzheimer's Disease. Quality of Life Research, 2006, 15, 631-643.	3.1	103
31	Impact of Androgen-Deprivation Therapy on Cognitive Function in Men With Nonmetastatic Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 5030-5037.	1.6	103
32	Is there age bias in the treatment of localized prostate carcinoma?. Cancer, 2004, 100, 72-81.	4.1	94
33	Modelling mitigation strategies for pandemic (H1N1) 2009. Cmaj, 2009, 181, 673-680.	2.0	94
34	Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis. Journal of Clinical Oncology, 2012, 30, 3167-3173.	1.6	94
35	Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU International, 2010, 105, 338-346.	2.5	91
36	A Review and Meta-Analysis of Prostate Cancer Utilities. Medical Decision Making, 2007, 27, 288-298.	2.4	90

#	ARTICLE	IF	CITATIONS
37	Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations. <i>Movement Disorders</i> , 2004, 19, 22-28.	3.9	89
38	The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 283-292.	6.7	87
39	End-of-Life Care for Lung Cancer Patients in the United States and Ontario. <i>Journal of the National Cancer Institute</i> , 2011, 103, 853-862.	6.3	86
40	Construction of the Patient-Oriented Prostate Utility Scale (PORPUS). <i>Journal of Clinical Epidemiology</i> , 2000, 53, 920-930.	5.0	85
41	Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. <i>CMAJ Open</i> , 2013, 1, E1-E8.	2.4	85
42	Cost Effectiveness of <i>EML4-ALK</i> Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced <i>ALK</i> -Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1012-1019.	1.6	85
43	Continued undertreatment of older men with localized prostate cancer. <i>Urology</i> , 2003, 62, 860-865.	1.0	83
44	The Effect of Cardiac Rehabilitation on Health-Related Quality of Life in Patients With Coronary Artery Disease: A Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2019, 35, 352-364.	1.7	80
45	Incremental health care costs for chronic pain in Ontario, Canada: a population-based matched cohort study of adolescents and adults using administrative data. <i>Pain</i> , 2016, 157, 1626-1633.	4.2	79
46	The economic burden of cancer care in Canada: a population-based cost study. <i>CMAJ Open</i> , 2018, 6, E1-E10.	2.4	79
47	Sustained Responders Have Better Quality of Life and Productivity Compared With Treatment Failures Long After Antiviral Therapy for Hepatitis C. <i>American Journal of Gastroenterology</i> , 2009, 104, 2439-2448.	0.4	78
48	Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. <i>Quality of Life Research</i> , 2007, 16, 509-522.	3.1	77
49	The Half-Cycle Correction Explained: Two Alternative Pedagogical Approaches. <i>Medical Decision Making</i> , 2008, 28, 706-712.	2.4	77
50	Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review. <i>Arthritis Care and Research</i> , 2011, 63, 65-78.	3.4	73
51	Estimation of Utilities for Chronic Hepatitis C from SF-36 Scores. <i>American Journal of Gastroenterology</i> , 2005, 100, 643-651.	0.4	72
52	Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1269-1277.	1.9	72
53	Should Canada and the United States Universally Vaccinate Infants against Hepatitis B?. <i>Medical Decision Making</i> , 1993, 13, 4-20.	2.4	71
54	Economic Appraisal of Ontario's Universal Influenza Immunization Program: A Cost-Utility Analysis. <i>PLoS Medicine</i> , 2010, 7, e1000256.	8.4	71

#	ARTICLE	IF	CITATIONS
55	Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer, 2016, 16, 809.	2.6	71
56	Lack of Comprehension of Common Prostate Cancer Terms in an Underserved Population. Journal of Clinical Oncology, 2009, 27, 2015-2021.	1.6	69
57	How Well Do Guidelines Incorporate Evidence on Patient Preferences?. Journal of General Internal Medicine, 2009, 24, 977-982.	2.6	69
58	Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet Journal of Rare Diseases, 2019, 14, 12.	2.7	68
59	The ten-year rule revisited: accuracy of clinicians's estimates of life expectancy in patients with localized prostate cancer. Urology, 2002, 60, 258-263.	1.0	67
60	Cost-effectiveness of screening for hepatitis C in Canada. Cmaj, 2015, 187, E110-E121.	2.0	65
61	Health care costs associated with hepatocellular carcinoma: A population-based study. Hepatology, 2013, 58, 1375-1384.	7.3	64
62	Pressure ulcer multidisciplinary teams via telemedicine: a pragmatic cluster randomized stepped wedge trial in long term care. BMC Health Services Research, 2014, 14, 83.	2.2	62
63	The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. Journal of the National Cancer Institute, 2016, 108, djv301.	6.3	62
64	Health utilities and psychometric quality of life in patients with early and late stage hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 149-157.	2.8	61
65	Health technology assessment: A comprehensive framework for evidence-based recommendations in Ontario. International Journal of Technology Assessment in Health Care, 2009, 25, 141-150.	0.5	60
66	Future Directions for Cost-effectiveness Analyses in Health and Medicine. Medical Decision Making, 2018, 38, 767-777.	2.4	58
67	Cost-Effectiveness Analyses of Hepatitis A Vaccine. Pharmacoeconomics, 2008, 26, 17-32.	3.3	57
68	Preventing Pressure Ulcers in Long-term Care. Archives of Internal Medicine, 2011, 171, 1839.	3.8	56
69	Content validity for dementia of three generic preference based health related quality of life instruments. Quality of Life Research, 2002, 11, 71-79.	3.1	55
70	Improved cognitive function as a consequence of hepatitis C virus treatment<sup>*</sup>. HIV Medicine, 2007, 8, 520-528.	2.2	55
71	Cost-Effectiveness of Specialized Multidisciplinary Heart Failure Clinics in Ontario, Canada. Value in Health, 2010, 13, 915-921.	0.3	55
72	Patients' and clinicians' experiences of wound care in Canada: a descriptive qualitative study. Journal of Wound Care, 2017, 26, S4-S13.	1.2	55

#	ARTICLE	IF	CITATIONS
73	Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. <i>Journal of General Internal Medicine</i> , 2004, 19, 339-348.	2.6	54
74	Health State Utilities and Quality of Life in Patients with Hepatitis B. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 445-451.	1.7	54
75	A Population-Based Study to Evaluate the Effectiveness of Multidisciplinary Heart Failure Clinics and Identify Important Service Components. <i>Circulation: Heart Failure</i> , 2013, 6, 68-75.	3.9	53
76	Comparative economic analyses of patient safety improvement strategies in acute care: a systematic review. <i>BMJ Quality and Safety</i> , 2012, 21, 448-456.	3.7	51
77	Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. <i>Cancer</i> , 2017, 123, 237-244.	4.1	51
78	Is there an optimal comorbidity index for prostate cancer?. <i>Cancer</i> , 2008, 112, 1043-1050.	4.1	50
79	Health Care Costs Associated with Hepatitis C: A Longitudinal Cohort Study. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2010, 24, 717-726.	1.7	50
80	Cost-effectiveness of Dalteparin vs Unfractionated Heparin for the Prevention of Venous Thromboembolism in Critically Ill Patients. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2135.	7.4	50
81	Valuing Health State: An EQ-5D-5L Value Set for Ethiopians. <i>Value in Health Regional Issues</i> , 2020, 22, 7-14.	1.2	50
82	Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. <i>Canadian Journal of Urology</i> , 2003, 10, 1891-8.	0.0	50
83	Techniques for estimating health care costs with censored data: an overview for the health services researcher. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 145.	1.9	49
84	Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. <i>Vaccine</i> , 2014, 32, 5436-5446.	3.8	48
85	Factors associated with the high cost of liver transplantation in adults. <i>Canadian Journal of Surgery</i> , 2002, 45, 425-34.	1.2	48
86	Cost effectiveness of screening immigrants for hepatitis B. <i>Liver International</i> , 2011, 31, 1179-1190.	3.9	47
87	Long-term impact of androgen-deprivation therapy on physical function and quality of life. <i>Cancer</i> , 2015, 121, 2350-2357.	4.1	47
88	Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. <i>Vaccine</i> , 2010, 28, 6210-6220.	3.8	46
89	Predictors of Patient Self-Ratings of Quality of Life in Alzheimer Disease: Cross-Sectional Results From the Canadian Alzheimer's Disease Quality of Life Study. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 881-890.	1.2	46
90	A Canadian national survey of attitudes and knowledge regarding preventive vaccines. <i>Journal of Immune Based Therapies and Vaccines</i> , 2003, 1, 3.	2.4	45

#	ARTICLE	IF	CITATIONS
91	Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990. Medical Decision Making, 2004, 24, 20-29.	2.4	45
92	Predicting preterm birth: A cost-effectiveness analysis. American Journal of Obstetrics and Gynecology, 2000, 182, 1589-1598.	1.3	44
93	Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporosis International, 2014, 25, 1225-1235.	3.1	44
94	Predictors of Family Caregiver Ratings of Patient Quality of Life in Alzheimer Disease: Cross-Sectional Results from the Canadian Alzheimer's Disease Quality of Life Study. American Journal of Geriatric Psychiatry, 2011, 19, 891-901.	1.2	43
95	An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data. Palliative Medicine, 2015, 29, 918-928.	3.1	43
96	Diagnostic accuracy of level IV portable sleep monitors versus polysomnography for obstructive sleep apnea: a systematic review and meta-analysis. Sleep and Breathing, 2018, 22, 593-611.	1.7	43
97	Incorporating Patient Preferences in Evidence-Based Medicine—Reply. JAMA - Journal of the American Medical Association, 2008, 300, 2483.	7.4	42
98	Management of decreased bone mineral density in men starting androgen deprivation therapy for prostate cancer. BJU International, 2009, 103, 753-757.	2.5	42
99	Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer. Journal of Clinical Epidemiology, 2005, 58, 466-474.	5.0	41
100	Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer, 2014, 14, 586.	2.6	41
101	The natural history of hepatitis C infection acquired through injection drug use: Meta-analysis and meta-regression. Journal of Hepatology, 2010, 53, 245-251.	3.7	40
102	The SARS outbreak in a general hospital in Tianjin, China — the case of super-spreader. Epidemiology and Infection, 2006, 134, 786-791.	2.1	39
103	Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada. Journal of Cancer Survivorship, 2014, 8, 9-20.	2.9	39
104	Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection. Journal of Viral Hepatitis, 2004, 11, 166-174.	2.0	38
105	Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. Osteoporosis International, 2013, 24, 2571-2579.	3.1	38
106	PROSTATE SPECIFIC ANTIGEN RESPONSE TO MITOXANTRONE AND PREDNISONE IN PATIENTS WITH REFRACTORY PROSTATE CANCER: PROGNOSTIC FACTORS AND GENERALIZABILITY OF A MULTICENTER TRIAL TO CLINICAL PRACTICE. Journal of Urology, 2000, 163, 1481-1485.	0.4	37
107	Health status utilities and the impact of pressure ulcers in long-term care residents in Ontario. Quality of Life Research, 2010, 19, 81-89.	3.1	37
108	Impact of rituximab on treatment outcomes of patients with diffuse large B-cell lymphoma: a population-based analysis. British Journal of Haematology, 2012, 158, 481-488.	2.5	37

#	ARTICLE	IF	CITATIONS
109	Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study. CMAJ Open, 2013, 1, E151-E158.	2.4	37
110	A multi-level qualitative analysis of Telehomecare in Ontario: challenges and opportunities. BMC Health Services Research, 2015, 15, 544.	2.2	37
111	Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment. HIV Medicine, 2007, 8, 192-202.	2.2	36
112	Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer. Value in Health, 2013, 16, 729-739.	0.3	36
113	Care in the Home for the Management of Chronic Heart Failure. Journal of Cardiovascular Nursing, 2015, 30, S44-S51.	1.1	36
114	Influence of Socioeconomic Status on Survival of Hepatocellular Carcinoma in the Ontario Population; A Population-Based Study, 1990â€“2009. PLoS ONE, 2012, 7, e40917.	2.5	36
115	Comparison of an Aggressive (U.S.) and a Less Aggressive (Canadian) Policy for Cholesterol Screening and Treatment. Annals of Internal Medicine, 1991, 115, 248-255.	3.9	35
116	Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation. Clinical Pharmacology: Advances and Applications, 2016, Volume 8, 93-107.	1.2	35
117	Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology) Tj ETQq1 1 0.784314 rgB34Overlo	1.2	35
118	The lifetime cost of spinal cord injury in Ontario, Canada: A population-based study from the perspective of the public health care payer. Journal of Spinal Cord Medicine, 2019, 42, 184-193.	1.4	34
119	A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. BMC Cancer, 2019, 19, 2.	2.6	34
120	Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine, 2005, 23, 1549-1558.	3.8	33
121	Utility and health-related quality of life in prostate cancer patients 12 months after radical prostatectomy or radiation therapy. Prostate Cancer and Prostatic Diseases, 2009, 12, 361-368.	3.9	33
122	Home Dialysis is Associated with Lower Costs and Better Survival than other Modalities: A Population-Based Study in Ontario, Canada. Peritoneal Dialysis International, 2019, 39, 553-561.	2.3	33
123	Coverage with evidence development: The Ontario experience. International Journal of Technology Assessment in Health Care, 2011, 27, 159-168.	0.5	32
124	Prescribing Gabapentin off Label: Perspectives from Psychiatry, Pain and Neurology Specialists. Canadian Pharmacists Journal, 2012, 145, 280-284.e1.	0.8	32
125	Health-Related Quality of Life Changes Associated With Hearing Loss. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 630.	2.2	32
126	The Half-Cycle Correction Revisited. Medical Decision Making, 2013, 33, 961-970.	2.4	31



#	ARTICLE	IF	CITATIONS
127	Cost-Utility Analysis of Primary Prophylaxis Versus Secondary Prophylaxis With Granulocyte Colony-Stimulating Factor in Elderly Patients With Diffuse Aggressive Lymphoma Receiving Curative-Intent Chemotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 1064-1071.	1.6	30
128	Vaccines in the public eye. <i>Nature Medicine</i> , 2005, 11, S20-S24.	30.7	29
129	Evaluating the ability to detect change of health-related quality of life in children with Hodgkin disease. <i>Cancer</i> , 2010, 116, 1608-1614.	4.1	29
130	Early Prevention of Pressure Ulcers Among Elderly Patients Admitted Through Emergency Departments: A Cost-effectiveness Analysis. <i>Annals of Emergency Medicine</i> , 2011, 58, 468-478.e3.	0.6	28
131	Specialized multi-disciplinary heart failure clinics in Ontario, Canada: an environmental scan. <i>BMC Health Services Research</i> , 2012, 12, 236.	2.2	28
132	A Survey of Patients' Preferences for the Treatment of Teeth with Apical Periodontitis. <i>Journal of Endodontics</i> , 2013, 39, 1534-1541.	3.1	28
133	Comparing Cancer Care, Outcomes, and Costs Across Health Systems: Charting the Course. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 124-130.	2.1	28
134	Does cirrhosis affect quality of life in hepatitis C virus-infected patients?. <i>Liver International</i> , 2009, 29, 449-458.	3.9	27
135	Development and Validation of a Utility Weighting Function for the Patient-Oriented Prostate Utility Scale (PORPUS). <i>Medical Decision Making</i> , 2012, 32, 11-30.	2.4	27
136	Initial Bone Marrow Aspiration in Childhood Idiopathic Thrombocytopenia: Decision Analysis. <i>The American Journal of Pediatric Hematology/oncology</i> , 2001, 23, 511-518.	1.3	26
137	The Effect of Hepatitis C Virus Infection on Health-Related Quality of Life in Prisoners. <i>Journal of Urban Health</i> , 2006, 83, 275-288.	3.6	26
138	Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic. <i>Journal of Hepatology</i> , 2008, 49, 711-717.	3.7	26
139	Identifying the Best Treatment Among Common Nonsurgical Neck Pain Treatments. <i>Spine</i> , 2008, 33, S184-S191.	2.0	26
140	The economic burden of patient safety targets in acute care: a systematic review. <i>Drug, Healthcare and Patient Safety</i> , 2012, 4, 141.	2.5	26
141	Costs for Childhood and Adolescent Cancer, 90 Days Prediagnosis and 1 Year Postdiagnosis: A Population-Based Study in Ontario, Canada. <i>Value in Health</i> , 2017, 20, 345-356.	0.3	26
142	Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. <i>BJU International</i> , 2018, 121, 17-28.	2.5	26
143	How Procurement Judges The Value of Medical Technologies: A Review of Healthcare Tenders. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 50-55.	0.5	26
144	Twenty-year secular changes in sex specific lung cancer incidence rates in an urban Chinese population. <i>Lung Cancer</i> , 2006, 51, 13-19.	2.0	25

#	ARTICLE	IF	CITATIONS
145	A review of interventions triggered by hepatitis A infected food-handlers in Canada. BMC Health Services Research, 2006, 6, 157.	2.2	25
146	Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. American Heart Journal, 2007, 154, 899-907.	2.7	25
147	Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?. BJU International, 2011, 108, 1588-1596.	2.5	25
148	Support surfaces for intraoperative prevention of pressure ulcers in patients undergoing surgery: A cost-effectiveness analysis. Surgery, 2011, 150, 122-132.	1.9	25
149	Predicting EQ-5D Utility Scores from the Seattle Angina Questionnaire in Coronary Artery Disease. Medical Decision Making, 2011, 31, 481-493.	2.4	25
150	A Survey of Dentists' Preferences for the Treatment of Teeth with Apical Periodontitis. Journal of Endodontics, 2013, 39, 1226-1233.	3.1	25
151	Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Systematic Reviews, 2019, 8, 207.	5.3	25
152	The association between patient age and prostate cancer stage and grade at diagnosis. BJU International, 2004, 94, 303-306.	2.5	24
153	An unadjusted NNT was a moderately good predictor of health benefit. Journal of Clinical Epidemiology, 2006, 59, 224-233.	5.0	24
154	Disease Burden of Chronic Hepatitis B among Immigrants in Canada. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 137-147.	1.7	24
155	A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. Value in Health, 2020, 23, 127-137.	0.3	24
156	Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. Breast Cancer Research and Treatment, 2016, 157, 535-544.	2.5	23
157	Patients' Values Related to Treatment Options for Teeth with Apical Periodontitis. Journal of Endodontics, 2016, 42, 365-370.	3.1	23
158	Model-based projection of health and economic effects of screening for hepatitis C in Canada. CMAJ Open, 2017, 5, E662-E672.	2.4	23
159	Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer—the 5C study: a study protocol for a randomised controlled phase III trial. BMJ Open, 2019, 9, e024485.	1.9	23
160	Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. BMJ Open, 2019, 9, e027491.	1.9	23
161	Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. Journal of Viral Hepatitis, 2021, 28, 739-754.	2.0	23
162	Management of Solitary 1â€‰cm to 2â€‰cm Liver Nodules in Patients with Compensated Cirrhosis: A Decision Analysis. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 491-500.	1.7	22

#	ARTICLE	IF	CITATIONS
163	A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada. <i>Quality of Life Research</i> , 2013, 22, 2951-2962.	3.1	22
164	QUANTITATIVE PATIENT PREFERENCE EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT: A CASE STUDY. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 290-300.	0.5	22
165	Health Care Costs for State Transition Models in Prostate Cancer. <i>Medical Decision Making</i> , 2014, 34, 366-378.	2.4	22
166	Health-related quality of life following radical prostatectomy: long-term outcomes. <i>Quality of Life Research</i> , 2014, 23, 2309-2317.	3.1	22
167	A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. <i>BMC Cancer</i> , 2015, 15, 312.	2.6	22
168	A population-based matched cohort study examining the mortality and costs of patients with community-onset <i>Clostridium difficile</i> infection identified using emergency department visits and hospital admissions. <i>PLoS ONE</i> , 2017, 12, e0172410.	2.5	22
169	The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer. <i>Journal of Urology</i> , 2018, 200, 283-291.	0.4	22
170	DEVELOPMENT OF THE ONTARIO DECISION FRAMEWORK: A VALUES BASED FRAMEWORK FOR HEALTH TECHNOLOGY ASSESSMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 290-299.	0.5	22
171	Sex or survival. <i>Cancer</i> , 2010, 116, 1909-1917.	4.1	21
172	Clinical Decision Making for a Tooth with Apical Periodontitis: The Patients' Preferred Level of Participation. <i>Journal of Endodontics</i> , 2014, 40, 784-789.	3.1	21
173	The Economic Burden of Hospital-Acquired <i>Clostridium difficile</i> Infection: A Population-Based Matched Cohort Study. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 1068-1078.	1.8	21
174	Factors affecting the delivery of community pharmacist-led medication reviews: evidence from the MedsCheck annual service in Ontario. <i>BMC Health Services Research</i> , 2016, 16, 666.	2.2	21
175	Principles of Economic Evaluation in Surgery. <i>World Journal of Surgery</i> , 1999, 23, 1242-1248.	1.6	20
176	Treatment of hepatitis C infection for current or former substance abusers in a community setting. <i>Journal of Viral Hepatitis</i> , 2009, 16, 557-567.	2.0	20
177	Patient time costs and out-of-pocket costs in hepatitis C. <i>Liver International</i> , 2012, 32, 815-825.	3.9	20
178	Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. <i>CMAJ Open</i> , 2017, 5, E97-E108.	2.4	20
179	Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis. <i>BJU International</i> , 2018, 122, 879-888.	2.5	20
180	Levels of sex hormones have limited effect on cognition in older men with or without prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 167-175.	4.4	19

#	ARTICLE	IF	CITATIONS
181	Early economic evaluation of emerging health technologies: protocol of a systematic review. <i>Systematic Reviews</i> , 2014, 3, 81.	5.3	19
182	Embracing the science of value in health. <i>Cmaj</i> , 2019, 191, E733-E736.	2.0	19
183	The emergency department as a setting-specific opportunity for population-based hepatitis C screening: An economic evaluation. <i>Liver International</i> , 2020, 40, 1282-1291.	3.9	19
184	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. <i>Healthcare Policy</i> , 2017, 12, 95-108.	0.6	19
185	Rethinking 30-day mortality risk after radical prostatectomy. <i>Urology</i> , 2006, 68, 1057-1060.	1.0	18
186	Health utilities in people with chronic pain using a population-level survey and linked health care administrative data. <i>Pain</i> , 2017, 158, 408-416.	4.2	18
187	Feasibility of Internet-Based Health-Related Quality of Life Data Collection in a Large Patient Cohort. <i>Journal of Medical Internet Research</i> , 2010, 12, e35.	4.3	18
188	Cohort effects in dynamic models and their impact on vaccination programmes: an example from Hepatitis A. <i>BMC Infectious Diseases</i> , 2006, 6, 174.	2.9	17
189	Issues in the Cost-Effectiveness of Asthma Education. <i>Chest</i> , 1994, 106, 264S-269S.	0.8	16
190	Azathioprine or Ileocolic Resection for Steroid-Dependent Terminal Ileal Crohn's Disease? A Markov Analysis. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 2120-2130.	1.3	16
191	Cost comparison of genetic and clinical screening in families with hereditary hemorrhagic telangiectasia. <i>American Journal of Medical Genetics, Part A</i> , 2005, 137A, 153-160.	1.2	16
192	Medical Therapy v. PCI in Stable Coronary Artery Disease. <i>Medical Decision Making</i> , 2013, 33, 891-905.	2.4	16
193	Changes in health utilities and health-related quality of life over 12 months following radical prostatectomy. <i>Canadian Urological Association Journal</i> , 2013, 3, 445.	0.6	16
194	Conceptualizing global health-related quality of life in bladder cancer. <i>Quality of Life Research</i> , 2014, 23, 2153-2167.	3.1	16
195	The Cost Effectiveness of ACE Inhibitors as First-Line Antihypertensive Therapy. <i>Pharmacoeconomics</i> , 2003, 21, 573-585.	3.3	15
196	Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort. <i>Journal of Viral Hepatitis</i> , 2009, 16, 802-813.	2.0	15
197	Immigrant patients with chronic hepatitis C and advanced fibrosis have a higher risk of hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2012, 19, 574-580.	2.0	15
198	Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines. <i>Vaccine</i> , 2014, 32, 3336-3340.	3.8	15

#	ARTICLE	IF	CITATIONS
199	Costs of cancer care in children and adolescents in Ontario, Canada. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26628.	1.5	15
200	Review of early assessment models of innovative medical technologies. <i>Health Policy</i> , 2017, 121, 870-879.	3.0	15
201	Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P). <i>BMC Cancer</i> , 2009, 9, 295.	2.6	14
202	Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. <i>Value in Health</i> , 2012, 15, 580-585.	0.3	14
203	Cost Effectiveness of Hepatitis C-Related Interventions Targeting Substance Users and Other High-Risk Groups. <i>Pharmacoeconomics</i> , 2012, 30, 1015-1034.	3.3	14
204	The Effect of Multidisciplinary Heart Failure Clinic Characteristics on 1-Year Postdischarge Health Care Costs. <i>Medical Care</i> , 2014, 52, 272-279.	2.4	14
205	Economic Evaluation of Hormonal Therapies for Postmenopausal Women with Estrogen Receptor-Positive Early Breast Cancer in Canada. <i>Current Oncology</i> , 2015, 22, 84-96.	2.2	14
206	Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. <i>BMC Cancer</i> , 2017, 17, 685.	2.6	14
207	Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). <i>Medical Decision Making</i> , 2019, 39, 371-379.	2.4	14
208	Predictors of Antiviral Therapy in a Post-Transfusion Cohort of Hepatitis C Patients. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2006, 20, 107-111.	1.7	13
209	Cost analysis of Greenlight photoselective vaporization of the prostate compared to transurethral resection of the prostate for benign prostatic hyperplasia. <i>Canadian Urological Association Journal</i> , 2018, 12, .	0.6	13
210	Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared with Deferring Treatment to Adulthood. <i>Journal of Pediatrics</i> , 2021, 230, 38-45.e2.	1.8	13
211	Implementation, spread and impact of the Patient Oriented Discharge Summary (PODS) across Ontario hospitals: a mixed methods evaluation. <i>BMC Health Services Research</i> , 2021, 21, 361.	2.2	13
212	Achieving Quality Indicator Benchmarks and Potential Impact on Coronary Heart Disease Mortality. <i>Canadian Journal of Cardiology</i> , 2011, 27, 756-762.	1.7	12
213	Insights Into the Contemporary Management of Heart Failure in Specialized Multidisciplinary Ambulatory Clinics. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1062-1068.	1.7	12
214	Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis. <i>CMAJ Open</i> , 2013, 1, E83-E90.	2.4	12
215	Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model. <i>BMC Public Health</i> , 2017, 17, 596.	2.9	12
216	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. <i>Healthcare Policy</i> , 2017, 12, 95-108.	0.6	12

#	ARTICLE	IF	CITATIONS
217	Gender Differences in Utilization of Specialized Heart Failure Clinics. <i>Journal of Women's Health</i> , 2018, 27, 623-629.	3.3	12
218	Resource Utilization and Costs in Adolescents Treated for Cancer in Pediatric vs Adult Institutions. <i>Journal of the National Cancer Institute</i> , 2019, 111, 322-330.	6.3	12
219	Chlorhexidine-Related Mortality Rate in Critically Ill Subjects in Intensive Care Units: A Systematic Review and Meta-Analysis. <i>Respiratory Care</i> , 2019, 64, 337-349.	1.6	12
220	On the integration of early health technology assessment in the innovation process: reflections from five stakeholders. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 481-485.	0.5	12
221	Prostate cancer screening: going beyond the clinical evidence. <i>Cmaj</i> , 2014, 186, 1201-1201.	2.0	11
222	Patients' preferences and trade-offs for the treatment of early stage hepatocellular carcinoma. <i>Journal of Surgical Research</i> , 2014, 189, 57-67.	1.6	11
223	Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 639-652.	2.5	11
224	Effects of six months of aerobic and resistance training on metabolic markers and bone mineral density in older men on androgen deprivation therapy for prostate cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1074-1077.	1.0	11
225	Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D and HUI-3 indices in patients with head and neck cancer. <i>Head and Neck</i> , 2020, 42, 2277-2286.		11
226	Prescribing patterns for Alzheimer disease: survey of Canadian family physicians. <i>Canadian Family Physician</i> , 2006, 52, 208-9.	0.4	11
227	Economic Issues in the Use of Office Spirometry for Lung Health Assessment. <i>Canadian Respiratory Journal</i> , 2003, 10, 320-326.	1.6	10
228	Indications for Interferon/Ribavirin Therapy in Hepatitis C Patients: Findings from a Survey of Canadian Hepatologists. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2003, 17, 183-186.	1.7	10
229	Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis—reply to Pazianas and Abrahamsen. <i>Osteoporosis International</i> , 2014, 25, 2671-2672.	3.1	10
230	Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 502.	1.6	10
231	Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. <i>CMAJ Open</i> , 2016, 4, E66-E72.	2.4	10
232	Decision making about healthcare-related tests and diagnostic test strategies. Paper 5: a qualitative study with experts suggests that test accuracy data alone is rarely sufficient for decision making. <i>Journal of Clinical Epidemiology</i> , 2017, 92, 47-57.	5.0	10
233	Mapping the University of Washington Quality of life questionnaire onto EQ-5D and HUI-3 indices in patients with head and neck cancer. <i>Head and Neck</i> , 2020, 42, 513-521.	2.0	10
234	Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1419-1429.	2.0	10

#	ARTICLE	IF	CITATIONS
235	High-Cost Patients and Preventable Spending: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 23-31.	4.9	10
236	Reliability and validity of using EQ-5D-5L among healthy and adolescents with major mental health disorders in Ethiopia. European Journal of Health Economics, 2022, 23, 1105-1119.	2.8	10
237	Cost-effectiveness analysis: are the outputs worth the inputs?. ACP Journal Club, 1996, 124, 82.	0.1	10
238	Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients. Quality of Life Research, 2007, 16, 1665-1675.	3.1	9
239	Understanding the role of scientific evidence in consumer evaluation of natural health products for osteoarthritis an application of the means end chain approach. BMC Complementary and Alternative Medicine, 2012, 12, 198.	3.7	9
240	Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS). Prostate Cancer and Prostatic Diseases, 2014, 17, 47-56.	3.9	9
241	Structure and characteristics of community-based multidisciplinary wound care teams in Ontario: An environmental scan. Wound Repair and Regeneration, 2015, 23, 22-29.	3.0	9
242	Predictors of diagnostic neuroimaging delays among adults presenting with symptoms suggestive of acute stroke in Ontario: a prospective cohort study. CMAJ Open, 2016, 4, E331-E337.	2.4	9
243	A Randomized Controlled Trial of an Exercise Maintenance Intervention in Men and Women After Cardiac Rehabilitation (ECO-PCR Trial). Canadian Journal of Cardiology, 2021, 37, 794-802.	1.7	9
244	Sex differences in direct healthcare costs following stroke: a population-based cohort study. BMC Health Services Research, 2021, 21, 619.	2.2	9
245	Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study. CMAJ Open, 2021, 9, E167-E174.	2.4	9
246	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. European Journal of Health Economics, 2022, 23, 1309-1317.	2.8	9
247	Guidelines for Verbal Presentations of Medical Decision Analyses. Medical Decision Making, 1997, 17, 228-230.	2.4	8
248	Economics of preventing premature mortality and impaired cognitive development in children through home-fortification: A health policy perspective. International Journal of Technology Assessment in Health Care, 2008, 24, 303-311.	0.5	8
249	Health-state utilities in a prisoner population: a cross-sectional survey. Health and Quality of Life Outcomes, 2009, 7, 78.	2.4	8
250	Identifying Future Research Priorities Using Value of Information Analyses: Left Atrial Appendage Occlusion Devices in Atrial Fibrillation. Journal of the American Heart Association, 2014, 3, e001031.	3.7	8
251	The ONCOTYROL Prostate Cancer Outcome and Policy Model. Medical Decision Making, 2015, 35, 758-772.	2.4	8
252	The Opportunity Cost of Capital. Inquiry (United States), 2015, 52, 004695801558464.	0.9	8



#	ARTICLE	IF	CITATIONS
253	Value of mesenchymal stem cell therapy for patients with septic shock: an early health economic evaluation. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 525-532.	0.5	8
254	International drug price comparisons: quality assessment. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2011, 29, 46-51.	1.1	8
255	The Role of the Ossific Nucleus in the Treatment of Established Hip Dislocation. <i>Clinical Orthopaedics and Related Research</i> , 2006, 449, 295-302.	1.5	7
256	Identifying the Best Treatment Among Common Nonsurgical Neck Pain Treatments. <i>Journal of Manipulative and Physiological Therapeutics</i> , 2009, 32, S209-S218.	0.9	7
257	“New” Evidence for Clinical Practice Guidelines. <i>Patient</i> , 2010, 3, 71-77.	2.7	7
258	How much are we spending? The estimation of research expenditures on cardiovascular disease in Canada. <i>BMC Health Services Research</i> , 2012, 12, 281.	2.2	7
259	Valuing Health Outcomes. , 2016, , 167-200.		7
260	The cost-utility of integrated cervical cancer prevention strategies in the Ontario setting “Can we do better?”. <i>Vaccine</i> , 2016, 34, 1936-1944.	3.8	7
261	SIESTA - Home sleep study with BresoDx for obstructive sleep apnea: a randomized controlled trial. <i>Sleep Medicine</i> , 2020, 65, 45-53.	1.6	7
262	Patterns of Care and Costs for Older Patients With Colorectal Cancer at the End of Life: Descriptive Study of the United States and Canada. <i>JCO Oncology Practice</i> , 2020, 16, e1-e18.	2.9	7
263	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , 2021, 22, 723-733.	2.8	7
264	Concordance of Couples’ Prostate Cancer Screening Recommendations from a Decision Analysis. <i>Patient</i> , 2008, 1, 11-19.	2.7	6
265	Another Look at the Human Papillomavirus Vaccine Experience in Canada. <i>American Journal of Public Health</i> , 2011, 101, 1850-1857.	2.7	6
266	Response to “The Life Table Method of Half-Cycle Correction: Getting It Right”. <i>Medical Decision Making</i> , 2014, 34, 286-287.	2.4	6
267	Using Cost-Effectiveness Analysis in Health and Medicine. , 2016, , 1-38.		6
268	Using Phase-Based Costing of Real-World Data to Inform Decision-Analytic Models for Atrial Fibrillation. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 313-322.	2.1	6
269	Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment. <i>Medical Decision Making</i> , 2016, 36, 375-390.	2.4	6
270	Changes in blood pressure among patients in the Ontario Telehomecare programme: An observational longitudinal cohort study. <i>Journal of Telemedicine and Telecare</i> , 2018, 24, 420-427.	2.7	6



#	ARTICLE	IF	CITATIONS
271	The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. <i>Liver International</i> , 2020, 40, 51-59.	3.9	6
272	Neck pain patients' preference scores for their current health. <i>Quality of Life Research</i> , 2010, 19, 687-700.	3.1	5
273	Use of a Catalytic Model to Estimate Hepatitis A Incidence in a Low-Endemicity Country. <i>Medical Decision Making</i> , 2012, 32, 167-175.	2.4	5
274	Ecologically optimizing exercise maintenance in men and women post-cardiac rehabilitation: Protocol for a randomized controlled trial of efficacy with economics (ECO-PCR). <i>Contemporary Clinical Trials</i> , 2016, 50, 116-123.	1.8	5
275	A model-based framework for chronic hepatitis C prevalence estimation. <i>PLoS ONE</i> , 2019, 14, e0225366.	2.5	5
276	Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study. <i>CMAJ Open</i> , 2021, 9, E897-E906.	2.4	5
277	Developing the Breast Utility Instrument, a preference-based instrument to measure health-related quality of life in women with breast cancer: Confirmatory factor analysis of the EORTC QLQ-C30 and BR45 to establish dimensions. <i>PLoS ONE</i> , 2022, 17, e0262635.	2.5	5
278	Incorporating economic evaluation into immunization decision making in Canada: a workshop. <i>Expert Review of Vaccines</i> , 2014, 13, 1291-1296.	4.4	4
279	A practical approach to evidence-based dentistry: IX. <i>Journal of the American Dental Association</i> , 2015, 146, 679-689.e1.	1.5	4
280	Disparities in a provision of in-hospital post-arrest interventions for out-of-hospital cardiac arrest (OHCA) in the elderly population—protocol for a systematic review. <i>Systematic Reviews</i> , 2016, 5, 55.	5.3	4
281	Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology. <i>Pharmacoeconomics - Open</i> , 2017, 1, 167-173.	1.8	4
282	Quality Improvement Summit 2016: Shared Decision Making and Prostate Cancer Screening. <i>Urology Practice</i> , 2018, 5, 444-451.	0.5	4
283	Lifetime cost of chronic ulcers requiring hospitalization in Ontario, Canada: A population-based study. <i>Wound Medicine</i> , 2018, 20, 21-34.	2.7	4
284	Carpal Tunnel Syndrome Management in Breast Cancer Survivors at Risk for Lymphedema: A Markov Model. <i>Plastic and Reconstructive Surgery</i> , 2018, 141, 689e-696e.	1.4	4
285	Comparative effectiveness of the different components of care provided in heart failure clinics—protocol for a systematic review and network meta-analysis. <i>Systematic Reviews</i> , 2019, 8, 40.	5.3	4
286	Long-term morbidity and mortality in a Canadian post-transfusion hepatitis C cohort: Over 15 years of follow-up. <i>Journal of Viral Hepatitis</i> , 2020, 27, 235-242.	2.0	4
287	Pharmacological Acromegaly Treatment: Cost-Utility and Value of Information Analysis. <i>Neuroendocrinology</i> , 2021, 111, 388-402.	2.5	4
288	Excess cost of care associated with sepsis in cancer patients: Results from a population-based case-control matched cohort. <i>PLoS ONE</i> , 2021, 16, e0255107.	2.5	4

#	ARTICLE	IF	CITATIONS
289	Association of Neighborhood-Level Material Deprivation With Health Care Costs and Outcome After Stroke. <i>Neurology</i> , 2021, 97, .	1.1	4
290	Recommendations on Perspectives for the Reference Case. , 2016, , 67-74.		4
291	Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience.. <i>PLOS Currents</i> , 2009, 1, RRN1137.	1.4	4
292	Modes of coordination for health technology adoption: Health Technology Assessment agencies and Group Procurement Organizations in a polycentric regulatory regime. <i>Social Science and Medicine</i> , 2020, 265, 113528.	3.8	4
293	“Bring the Hoses to Where the Fire Is”: Differential Impacts of Marginalization and Socioeconomic Status on COVID-19 Case Counts and Healthcare Costs. <i>Value in Health</i> , 2022, 25, 1307-1316.	0.3	4
294	Beyond case fatality rate: using potential impact fraction to estimate the effect of increasing treatment uptake on mortality. <i>BMC Medical Research Methodology</i> , 2013, 13, 109.	3.1	3
295	Canada's Contribution to Global Research in Cardiovascular Diseases. <i>Canadian Journal of Cardiology</i> , 2013, 29, 742-746.	1.7	3
296	Systematic Review, Critical Appraisal, and Analysis of the Quality of Economic Evaluations in Stroke Imaging. <i>Stroke</i> , 2014, 45, 807-814.	2.0	3
297	Adaptation and validation of the Spanish version of the Patient-Oriented Prostate Utility Scale (PORPUS). <i>Quality of Life Research</i> , 2014, 23, 2481-2487.	3.1	3
298	Use of forecasted assessment of quality of life to validate time-trade-off utilities and a prostate cancer screening decision-analytic model. <i>Health Expectations</i> , 2015, 18, 1610-1620.	2.6	3
299	The characteristics of stroke units in Ontario: a pan-provincial survey. <i>BMC Health Services Research</i> , 2017, 17, 154.	2.2	3
300	Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT. <i>BMC Cancer</i> , 2018, 18, 1031.	2.6	3
301	Exploring the Benefits of Transformations in Health Utility Mapping. <i>Medical Decision Making</i> , 2020, 40, 183-197.	2.4	3
302	Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System. <i>Value in Health</i> , 2022, 25, 247-256.	0.3	3
303	Compulsory school-entry vaccination laws and exemptions: who is opting out in ontario and why does it matter?. <i>Healthcare Policy</i> , 2010, 5, 37-46.	0.6	3
304	Health Economic and Infectious Disease Modelling. <i>Pharmacoeconomics</i> , 2011, 29, 367-369.	3.3	2
305	The Future of Health Technology Assessment. <i>Medical Decision Making</i> , 2012, 32, 7-8.	2.4	2
306	Economic analysis of Heart and Stroke Foundation of Ontario's Hypertension Management Initiative. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 323.	1.9	2

#	ARTICLE	IF	CITATIONS
307	Disease burden of chronic hepatitis C among immigrants in Canada. Journal of Viral Hepatitis, 2015, 22, 1043-1054.	2.0	2
308	Canadian hepatitis C virus screening guideline: a disconnect between evidence and recommendations. Cmaj, 2017, 189, E1150-E1150.	2.0	2
309	Preferences of Pregnant Women and Family Members for Health States Arising From Anticoagulant Use in Pregnancy [17N]. Obstetrics and Gynecology, 2017, 129, S147-S147.	2.4	2
310	Health Care Use and Associated Time and Out of Pocket Expenditures for Patients With Cardiovascular Disease in a Publicly Funded Health Care System. Canadian Journal of Cardiology, 2018, 34, 52-60.	1.7	2
311	Direct and indirect utilities of patients with mild to moderate versus severe carpal tunnel syndrome. Journal of Hand Surgery: European Volume, 2020, 45, 832-837.	1.0	2
312	Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis. CMAJ Open, 2021, 9, E886-E896.	2.4	2
313	Principles of economic evaluation in cancer screening. Cancer Treatment and Research, 1996, 86, 25-40.	0.5	2
314	Comparing Childhood Cancer Care Costs in Two Canadian Provinces. Healthcare Policy, 2020, 15, 76-88.	0.6	2
315	Turning for Ulcer Reduction (TURN) Study: An Economic Analysis. Ontario Health Technology Assessment Series, 2014, 14, 1-24.	1.8	2
316	No Time to Waste: An Appraisal of Value at the End of Life. Value in Health, 2022, 25, 1902-1909.	0.3	2
317	Identifying the Best Treatment Among Common Nonsurgical Neck Pain Treatments. European Spine Journal, 2008, 17, 184-191.	2.2	1
318	Turning High-Risk Individuals: An Economic Evaluation of Repositioning Frequency in Long-Term Care. Journal of the American Geriatrics Society, 2018, 66, 1409-1414.	2.6	1
319	Health Utility Book (HUB) – Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer. MDM Policy and Practice, 2019, 4, 238146831985259.	0.9	1
320	Review of Pharmacoeconomic Studies in Russian Cancer Research: An Outside View. Value in Health Regional Issues, 2019, 19, 138-144.	1.2	1
321	SIGNIFICANCE OF THE CAG REPEAT POLYMORPHISM OF THE ANDROGEN RECEPTOR GENE IN PROSTATE CANCER PROGRESSION. Journal of Urology, 2000, , 567-572.	0.4	1
322	PROSTATE SPECIFIC ANTIGEN RESPONSE TO MITOXANTRONE AND PREDNISONE IN PATIENTS WITH REFRACTORY PROSTATE CANCER:. Journal of Urology, 2000, , 1481-1485.	0.4	1
323	Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis against Febrile Neutropenia in Lymphoma Patients Receiving R-CHOP Chemotherapy.. Blood, 2009, 114, 2475-2475.	1.4	1
324	Strategies to achieve population control of HCV infection: results of a multidisciplinary focus group. Canadian Liver Journal, 2020, 3, 224-231.	0.9	1

#	ARTICLE	IF	CITATIONS
325	Review: ribavirin is not better than placebo in chronic hepatitis C infection. ACP Journal Club, 2006, 145, 47.	0.1	1
326	Review: Alpha-interferon terminates viral replications and eradicates the carrier state in chronic hepatitis B virus infection. ACP Journal Club, 1994, 120, 12.	0.1	1
327	Screening for Prostate Cancer-Reply. JAMA - Journal of the American Medical Association, 1995, 273, 1175.	7.4	0
328	Prevention of hepatitis B virus transmission by immunization: An economic analysis of current recommendations. Journal of Pediatrics, 1996, 128, 715-716.	1.8	0
329	RESPONSE: Re: 30-Day Mortality and Major Complications after Radical Prostatectomy: Influence of Age and Comorbidity. Journal of the National Cancer Institute, 2006, 98, 421-422.	6.3	0
330	PCN54 A COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS VERSUS SECONDARY PROPHYLAXIS WITH COLONY-STIMULATING FACTOR IN ELDERLY PATIENTS WITH DIFFUSE AGGRESSIVE LYMPHOMA RECEIVING CURATIVE-INTENT CHEMOTHERAPY USING ONTARIO HEALTH ECONOMIC DATA. Value in Health, 2008, 11, A70-A71.	0.3	0
331	PIN2 A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF PEGYLATED INTERFERON, LAMIVUDINE, ADEFOVIR AND ENTECAVIR FORTHETREATMENT OF HEPATITIS B. Value in Health, 2008, 11, A92-A93.	0.3	0
332	PIN43 NATURAL HISTORY OF CHRONIC HCV INFECTION OBTAINED THROUGH INJECTION DRUG USE: A BAYESIAN META-ANALYSIS. Value in Health, 2008, 11, A105-A106.	0.3	0
333	Screening for HCV. Cmaj, 2014, 186, 294.1-294.	2.0	0
334	Performance of the disease risk score in a cohort study with policy-induced selection bias. Journal of Comparative Effectiveness Research, 2015, 4, 607-614.	1.4	0
335	Low-Dose-Rate Brachytherapy versus. Standard Fractionated External Beam Radiotherapy versus. Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Cost-Utility Analysis. Brachytherapy, 2016, 15, S96-S97.	0.5	0
336	Reply. Pain, 2016, 157, 1834-1834.	4.2	0
337	Authorsâ€™ response. Journal of the American Dental Association, 2016, 147, 6-7.	1.5	0
338	Using a Health Economic Framework to Prioritize Quality Indicators: An Example With Smoking Cessation in Chronic Obstructive Pulmonary Disease. MDM Policy and Practice, 2019, 4, 238146831985235.	0.9	0
339	New Insights into the Epidemiology of Prostate Cancer in Ontario. Cancer Investigation, 2019, 37, 513-523.	1.3	0
340	Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in Health Technology Assessment in Canada. International Journal of Technology Assessment in Health Care, 2020, 36, 40-49.	0.5	0
341	Understanding resource utilization and mortality in COPD to support policy making: A microsimulation study. PLoS ONE, 2020, 15, e0236559.	2.5	0
342	Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT). Pharmacoeconomics, 2021, 39, 1075-1084.	3.3	0

#	ARTICLE	IF	CITATIONS
343	PedsQL <sup>®</sup> and EuroQol Most Responsive Measures To Change in Health-Related Quality of Life in Children with Hodgkin's Disease.. Blood, 2005, 106, 1320-1320.	1.4	0
344	Decision analysis in aerospace medicine: costs and benefits of a hyperbaric facility in space. Aviation, Space, and Environmental Medicine, 2006, 77, 434-42; discussion 442-3.	0.5	0
345	Abstract P4-12-11: Eq-5d-5l utility scores for patients with breast cancer. Cancer Research, 2022, 82, P4-12-11-P4-12-11.	0.9	0
346	Pravastatin reduced total and LDL cholesterol more than gemfibrozil in primary hypercholesterolemia. ACP Journal Club, 1991, 114, 77.	0.1	0
347	Screening newborns plus universal vaccination of 10-year olds was the most cost effective hepatitis B vaccination strategy. ACP Journal Club, 1993, 118, 93.	0.1	0
348	Simvastatin was cost-effective in lowering cholesterol in coronary heart disease. ACP Journal Club, 1997, 127, 21.	0.1	0
349	Review: Plasma-derived hepatitis B vaccine is safe and effective for health care workers. ACP Journal Club, 1998, 128, 45.	0.1	0